EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.
The enhancer of zeste homolog 2 (EZH2) plays a critical role in different components of anti-tumor immunity. However, the specific role of EZH2 in modulating MHC Class I antigen presentation and T cell infiltration have not been investigated in HCC. This study analyzed the expression and clinical si...
Main Authors: | Baoping Guo, Xiaohong Tan, Hong Cen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0242191 |
Similar Items
-
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
by: Gang Xiao, et al.
Published: (2019-11-01) -
Aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma.
by: Yi Zhang, et al.
Published: (2014-01-01) -
Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.
by: Yung-Luen Yu, et al.
Published: (2013-01-01) -
A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
by: Hong Cen, et al.
Published: (2015-01-01) -
MAPK10 Expression as a Prognostic Marker of the Immunosuppressive Tumor Microenvironment in Human Hepatocellular Carcinoma
by: Huahui Li, et al.
Published: (2021-08-01)